Marksans Pharma Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
6/10
|
22.76 | 56.11 | -59.43% | 12.62 | +80.37% |
| P/S |
|
3.28 | 17.79 | -81.57% |
|
|
| P/BV |
|
3.42 | 8.08 | -57.64% |
|
|
| P/FCF |
|
194.96 | -381.8 | -151.06% |
|
|
| Ev/Ebitda |
|
9.05 | 4.22 | 114.7% |
|
|
| Ev/S |
|
1.66 | 16.49 | -89.95% |
|
|
| Ev/FCF |
|
167.32 | -240.24 | -169.65% |
|
|
| E/P |
|
0.0746 | 0.0159 | 368.71% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
7/10
|
21.52 | -18.77 | -214.62% | 20.9 | +2.97% |
| ROE |
|
15.19 | 3.69 | 312.13% |
|
|
| ROA |
|
11.7 | 3.44 | 239.89% |
|
|
| ROIC |
|
0 | 11.26 | -100% |
|
|
| ROS |
|
14.41 | -47.96 | -130.05% |
|
|
| ROCE |
|
0 | 5.09 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0.3083 | 24.38 | -98.74% | 0.2944 | +4.72% |
| Nеt Debt/Ebitda |
|
0 | 21.3 | -100% |
|
|
| Debt/Ratio |
|
0.0459 | 0.126 | -63.57% |
|
|
| Debt/Equity |
|
0.3178 | 4.64 | -93.14% |
|
|
| Debt/Net Income |
|
0.3921 | -49.02 | -100.8% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.6496 | -100% | 0.4193 | -100% |
| Number of years of dividend growth |
|
1 | 0.92 | 8.7% | ||
| DSI |
|
1 | 0.8171 | 22.38% |
|
|
| Average dividend growth |
|
29.44 | 1.6 | 1741.78% |
|
|
| Average percentage for 5 years |
|
0.4193 | 0.8856 | -52.66% |
|
|
| Average percentage for payments |
|
31.24 | 22.22 | 40.61% |
|
|
| Difference from average difference in sector |
|
-0.6496 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
9/10
|
91.98 | 72.87 | 26.22% | ||
| Growth impulse Ebitda in 5 years |
|
111.33 | 72.97 | 52.57% | ||
| Growth impulse Net Income in 5 years |
|
168.08 | 159.06 | 5.67% | ||
| Growth impulse FCF in 5 years |
|
-85.65 | 85.7 | -199.94% | ||
| Growth impulse EPS in 5 years |
|
231.94 | 104.61 | 121.72% |
IP Score
6.17/10
